“ϊ–{ˆγ‰Θ‘εŠwˆγŠw‰οŽGŽ Online Journal ƒƒCƒ“ƒiƒrƒQ[ƒVƒ‡ƒ“‚π”ς‚Ξ‚·
‘–ΪŽŸ > †–ΪŽŸ > Abstract ƒz[ƒ€‚Φ–ί‚ι
Abstract

‘ζ14Šͺ 2018”N10ŒŽ@‘ζ4†

‘S•ΆPDF (327K)

‘“ΑWkŠeŽνŠΰ‚Μ•ͺŽq•W“I—Γ–@‚ΜŒ»‹΅‚Ζ“WŠJl‘ζ28‰ρŒφŠJuƒVƒ“ƒ|ƒWƒEƒ€v

–«œ‘«”’ŒŒ•a‚Ι‚έ‚ι‘’ŒŒŠνŽξᇔ­Ά‚ΜƒƒJƒjƒYƒ€‚ΖŽ‘—Γ–@‚ΜŠJ”­`From bench to bedside`
Œγ“‘@–Ύ•F
‡“V“°‘εŠwˆγŠw•”“ΰ‰ΘŠwŒŒ‰tŠwuΐ

Elucidation of the Pathogenesis of Chronic Myelogenous Leukemia and Development of its Treatment`From Bench to Bedside`
Akihiko Gotoh
Department of Hematology, Juntendo University School of Medicine

“ϊˆγ‘εˆγ‰οŽ 2018; 14(4), 173-176

Key words
chronic myelogenous leukemia, Philadelphia chromosome, BCR-ABL, tyrosine kinase inhibitor

Correspondence to
Akihiko Gotoh, Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan
E-mailFakgotou@juntendo.ac.jp

Žσ•tF2018”N8ŒŽ13“ϊ@Žσ—F2018”N8ŒŽ27“ϊ

ƒƒCƒ“ƒiƒrƒQ[ƒVƒ‡ƒ“‚Φ–ί‚ι ‚±‚Μƒy[ƒW‚Μƒgƒbƒv‚Φ–ί‚ι